Hyperscale Data, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Hyperscale Data, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $52.40M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $23.87M | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $22.36M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $27.15M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $10.17M | Oct 16, 2019 |
| FY2017 | Dec 31, 2016 | $7.60M | Apr 18, 2018 |
| FY2016 | Dec 31, 2015 | $7.77M | Apr 10, 2017 |
| FY2015 | Dec 31, 2014 | $9.02M | Mar 31, 2016 |
| FY2014 | Dec 31, 2013 | $8.77M | Mar 27, 2015 |
| FY2013 | Dec 31, 2012 | $8.59M | Mar 28, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.57M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $24.22M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $24.78M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $50.68M | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | $28.54M | May 22, 2023 |
| FY2021 | Dec 31, 2020 | $7.51M | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $3.06M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $5.38M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $3.85M | Oct 16, 2019 |
| FY2017 | Dec 31, 2016 | $2.71M | Apr 18, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($66.40M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($56.20M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($231.03M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($181.82M) | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | ($23.25M) | May 22, 2023 |
| FY2021 | Dec 31, 2020 | ($29.42M) | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | ($32.91M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($32.23M) | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | ($10.62M) | Oct 16, 2019 |
| FY2017 | Dec 31, 2016 | ($1.12M) | Apr 18, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($62.27M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($56.97M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($149.30M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($139.48M) | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | ($18.36M) | May 22, 2023 |
| FY2021 | Dec 31, 2020 | ($6.03M) | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | ($24.70M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($19.61M) | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | ($5.98M) | Oct 16, 2019 |
| FY2017 | Dec 31, 2016 | ($1.22M) | Apr 18, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.83M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $11.01M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $4.42M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.77M | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | $2.04M | May 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.85M | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $1.86M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.43M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $1.12M | Oct 16, 2019 |
| FY2017 | Dec 31, 2016 | $709.0K | Apr 18, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($62.52M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($19.41M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($5.43M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $26.49M | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | ($61.67M) | May 22, 2023 |
| FY2021 | Dec 31, 2020 | ($11.18M) | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | ($10.18M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($10.42M) | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | ($4.12M) | Oct 16, 2019 |
| FY2017 | Dec 31, 2016 | ($358.0K) | Apr 18, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.54M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $4.83M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $14.74M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $99.31M | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | $151.99M | May 22, 2023 |
| FY2021 | Dec 31, 2020 | $582.0K | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $189.3K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $8.92M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $402.8K | Oct 16, 2019 |
| FY2017 | Dec 31, 2016 | $85.0K | Apr 18, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $313.71M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $220.77M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $299.19M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $561.51M | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | $490.29M | May 22, 2023 |
| FY2021 | Dec 31, 2020 | $75.64M | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $42.75M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $49.43M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $30.51M | Oct 16, 2019 |
| FY2017 | Dec 31, 2016 | $5.47M | Apr 18, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.85M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $218.68M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $240.29M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $337.53M | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | $145.11M | May 22, 2023 |
| FY2021 | Dec 31, 2020 | $26.51M | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $35.80M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $31.36M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $11.72M | Oct 16, 2019 |
| FY2017 | Dec 31, 2016 | $1.91M | Apr 18, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.76M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $8.64M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $44.72M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $206.49M | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | $226.84M | May 22, 2023 |
| FY2021 | Dec 31, 2020 | $48.31M | Apr 14, 2023 |
| FY2021 | Jan 1, 2020 | $6.94M | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $6.94M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $18.02M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $18.01M | Oct 16, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.33M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $295.0K | Apr 15, 2026 |
| FY2023 | Dec 31, 2023 | $6.09M | Sep 24, 2024 |
| FY2023 | Dec 31, 2022 | $27.90M | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | $10.09M | May 22, 2023 |
| FY2022 | Dec 31, 2020 | $9.65M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $8.10M | Apr 14, 2023 |
| FY2020 | Dec 31, 2018 | $8.20M | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $3.65M | Jun 1, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($734.56M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($628.95M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($567.47M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($329.08M) | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | ($145.60M) | May 22, 2023 |
| FY2021 | Dec 31, 2020 | ($122.33M) | Apr 14, 2023 |
| FY2021 | Jan 1, 2020 | ($92.90M) | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | ($88.65M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($55.72M) | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | ($23.41M) | Oct 16, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.08M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $4.55M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $6.11M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $7.94M | Sep 24, 2024 |
| FY2022 | Dec 31, 2021 | $15.91M | May 22, 2023 |
| FY2021 | Dec 31, 2020 | $18.68M | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $483.4K | Apr 15, 2021 |
| FY2020 | Dec 31, 2018 | $769.6K | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $1.48M | Jun 1, 2020 |
| FY2018 | Dec 31, 2016 | $996.2K | Oct 16, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.12M | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | $96.67M | Apr 15, 2025 |
| FY2023 | Dec 31, 2023 | $31.11M | Sep 24, 2024 |
| FY2022 | Dec 31, 2022 | $144.17M | May 22, 2023 |
| FY2016 | Dec 31, 2016 | $34.0K | Apr 10, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (68) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (2,192) | Apr 15, 2025 |
| FY2022 | Dec 31, 2022 | 0 | May 22, 2023 |
| FY2022 | Dec 31, 2021 | 0 | May 22, 2023 |
| FY2012 | Dec 31, 2012 | 0 | Mar 29, 2013 |
| FY2012 | Dec 31, 2011 | 0 | Mar 29, 2013 |
| FY2011 | Dec 31, 2010 | 0 | Oct 9, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (68) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (2,192) | Apr 15, 2025 |
| FY2022 | Dec 31, 2022 | 0 | May 22, 2023 |
| FY2022 | Dec 31, 2021 | 0 | May 22, 2023 |
| FY2012 | Dec 31, 2012 | 0 | Mar 29, 2013 |
| FY2012 | Dec 31, 2011 | 0 | Mar 29, 2013 |
| FY2011 | Dec 31, 2010 | 0 | Oct 9, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | 7.68M | Apr 10, 2017 |
| FY2016 | Dec 31, 2015 | 6.78M | Apr 10, 2017 |
| FY2015 | Dec 31, 2014 | 6.85M | Mar 31, 2016 |
| FY2014 | Dec 31, 2013 | 6.85M | Mar 27, 2015 |
| FY2013 | Dec 31, 2012 | 6.85M | Mar 28, 2014 |
| FY2012 | Dec 31, 2011 | 6.85M | Mar 29, 2013 |
| FY2011 | Dec 31, 2010 | 6.70M | Oct 9, 2012 |